A bill passed by Congress last month did not include a proposed provision to require drug and device makers to divulge clinical trial results for products that have not yet been approved, which may prevent some patients enrolled in clinical studies from learning about the findings, experts say. Manufacturers express concern that disclosure of such data could have anti-competitive consequences, particularly for small businesses.

Full Story:

Related Summaries